Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting

Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings underscore the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2024-07, Vol.17 (1), p.52-3, Article 52
Main Authors: An, Zhuo-Yu, Zhang, Xiao-Hui
Format: Article
Language:English
Subjects:
5-aza-2'-deoxycytidine
Acute myeloid leukemia
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemotherapy
Clinical trials
Correspondence
Humans
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Menin inhibitors
Mutation
Proto-Oncogene Proteins - antagonists & inhibitors
Remission (Medicine)
Response rates
Revumenib
Stem cell transplantation
Ziftomenib
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings underscore the potential of menin inhibitors in transforming AML treatment, particularly in genetically defined subgroups, offering hope for improved patient outcomes. Ongoing studies, like KOMET-008, further explore the synergistic potential of menin inhibitors in combination regimens, shaping future AML management strategies.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-024-01573-2